Cargando…
Comment on: Benchmarking tocilizumab use for giant cell arteritis
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9479882/ https://www.ncbi.nlm.nih.gov/pubmed/36133959 http://dx.doi.org/10.1093/rap/rkac069 |
| _version_ | 1784790894240595968 |
|---|---|
| author | Janagan, Shalini Guly, Catherine Skeoch, Sarah Robson, Joanna C |
| author_facet | Janagan, Shalini Guly, Catherine Skeoch, Sarah Robson, Joanna C |
| author_sort | Janagan, Shalini |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9479882 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Oxford University Press |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94798822022-09-20 Comment on: Benchmarking tocilizumab use for giant cell arteritis Janagan, Shalini Guly, Catherine Skeoch, Sarah Robson, Joanna C Rheumatol Adv Pract Letter to the Editor (Matters arising from published papers) Oxford University Press 2022-08-23 /pmc/articles/PMC9479882/ /pubmed/36133959 http://dx.doi.org/10.1093/rap/rkac069 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Rheumatology. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Letter to the Editor (Matters arising from published papers) Janagan, Shalini Guly, Catherine Skeoch, Sarah Robson, Joanna C Comment on: Benchmarking tocilizumab use for giant cell arteritis |
| title | Comment on: Benchmarking tocilizumab use for giant cell arteritis |
| title_full | Comment on: Benchmarking tocilizumab use for giant cell arteritis |
| title_fullStr | Comment on: Benchmarking tocilizumab use for giant cell arteritis |
| title_full_unstemmed | Comment on: Benchmarking tocilizumab use for giant cell arteritis |
| title_short | Comment on: Benchmarking tocilizumab use for giant cell arteritis |
| title_sort | comment on: benchmarking tocilizumab use for giant cell arteritis |
| topic | Letter to the Editor (Matters arising from published papers) |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9479882/ https://www.ncbi.nlm.nih.gov/pubmed/36133959 http://dx.doi.org/10.1093/rap/rkac069 |
| work_keys_str_mv | AT janaganshalini commentonbenchmarkingtocilizumabuseforgiantcellarteritis AT gulycatherine commentonbenchmarkingtocilizumabuseforgiantcellarteritis AT skeochsarah commentonbenchmarkingtocilizumabuseforgiantcellarteritis AT robsonjoannac commentonbenchmarkingtocilizumabuseforgiantcellarteritis |